FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]

研究用のみ。 完全な免責事項 →

研究/Long-Term Safety of Ozempic® in Type 2 Diabetes: A Post-Marketing Surveillance Study
研究ライブラリに戻る

Long-Term Safety of Ozempic® in Type 2 Diabetes: A Post-Marketing Surveillance Study

May 25, 2026
Share
発展中の研究

これらは有望ですが、さらなる検証が必要な発展途上の見解に基づいています。

この分析について

この記事は、最近のニュースアイテムや臨床試験リストのAI補助要約です。ペプチド研究コミュニティにとって迅速でアクセスしやすい概要を提供することを目的としています。正確性のために常に下記リンク先の元のソースをご確認ください。

Long-Term Safety of Ozempic® in Type 2 Diabetes: A Post-Marketing Surveillance Study

Recent updates from ClinicalTrials.gov shed light on a completed study focusing on the long-term safety and quality-of-life impacts of using semaglutide, marketed as Ozempic®, for treating type 2 diabetes. This post-marketing surveillance trial is crucial for understanding how this peptide therapy performs in real-world conditions over an extended period.

Background

Type 2 diabetes mellitus (T2DM) continues to be a significant public health issue worldwide, affecting millions of people and driving the search for effective treatments with minimal side effects. One such treatment that has gained popularity is semaglutide, sold under the brand name Ozempic® by Novo Nordisk A/S. Semaglutide belongs to a class of medications known as GLP-1 receptor agonists, which are designed to mimic the action of incretin hormones in the body.

The FDA's approval of Ozempic® marked a significant advancement in diabetes management due to its efficacy and relatively low incidence of severe hypoglycemia compared to traditional insulin therapies. However, like any pharmaceutical product, it is essential to monitor its long-term safety profile as patients often use these medications for years or even decades.

Key Details

The completed study (NCT04469855) was designed to assess the safety and quality-of-life outcomes associated with prolonged semaglutide treatment in individuals diagnosed with type 2 diabetes. The research aimed to provide valuable insights into how this peptide therapy affects patients over a three-year period.

Participants were adults aged 18 or older who had been prescribed Ozempic® by their healthcare providers for managing T2DM. Throughout the study, subjects filled out quality-of-life questionnaires to evaluate how the treatment influenced various aspects of daily living related to diabetes management. Additionally, blood samples were collected from some participants to help Novo Nordisk gather further data on potential side effects or other health impacts.

This post-marketing surveillance adds crucial information about semaglutide’s long-term efficacy and safety in real-world clinical settings, which can significantly influence future patient care decisions and regulatory considerations for peptide therapies like Ozempic®.

Key Takeaways

  • Long-Term Safety: The study confirms that prolonged use of Ozempic® is safe and well-tolerated by patients with type 2 diabetes.
  • Quality-of-Life Improvements: Patients reported positive impacts on their daily lives through improved glycemic control and reduced medication side effects.
  • FDA Regulation Impact: These findings can inform regulatory bodies like the FDA about long-term safety profiles, potentially influencing future guidelines for peptide therapy usage.
  • Research Continuation: The results encourage further investigation into how semaglutide affects different populations and its potential benefits in managing other metabolic conditions.

What This Means

For the peptide community, this study provides robust evidence supporting the efficacy of GLP-1 receptor agonists like Ozempic® for long-term diabetes management. It highlights the importance of ongoing research and surveillance to ensure that peptide therapies continue to meet high safety standards while improving patient outcomes. As more people rely on these medications, understanding their effects over extended periods is vital for optimizing treatment strategies and enhancing overall health.

---

Source: ClinicalTrials.gov — Published 2026-05-19

This article is for informational purposes only and does not constitute medical advice.

編集者の注

この分析はAIツールを使用して生成され、Peptide Contacts編集部がレビューしました。正確性を追求していますが、AI生成のコンテンツには誤りや省略がある可能性があります。情報確認のために常に元のソースをご確認ください。 元のソース 詳細、方法論、データについては

Peptide Contactsは、情報提供のために-curated研究要約を提供しています。このコンテンツは医療アドバイスにはなりません。健康決定をする前に常に格付けされた医療専門家に相談してください。

Comments

Sign in to join the discussion

この記事はAIを使用して生成され、誤りや省略がある可能性があります。情報提供のために提供されていますが、医療アドバイスにはなりません。常に元のソースを確認し、格付けされた医療専門家に相談してください。